Literature DB >> 2556020

Lymphoepithelial cystic lesion related to adenocarcinoma in the mediastinum.

Y Ishimaru1, Y Shibata, S Ohkawara, H Ohshima, S Kihara.   

Abstract

The authors report here a case of lymphoepithelial cystic lesion (LECL) of unknown origin in the mediastinum, which is closely related to a signet-ring cell adenocarcinoma. A 73-year-old man presented with a mass as revealed on a chest x-ray. During surgical operation, a solid, well-circumscribed and encapsulated 9 X 9 X 8 cm tumor was isolated from the right anterior mediastinum. This tumor had neither undergone metastasis nor invaded into the surrounding tissue and lymph nodes. Light microscopy revealed the tumor to be a signet-ring cell adenocarcinoma. Clinically, the neoplasm was coupled with an elevation in serum CEA level, which promptly returned to normal values following surgical removal. Immunohistochemistry pointed out that the majority of neoplastic cells stained positive for CEA. In addition, LECL of unknown origin was distinguished at the periphery of the tumor. LECL was characterized by microcysts which were lined by columnar epithelial and surrounded by lymphoid tissue with germinal centers. Transition between the neoplastic cells and benign epithelial cells of LECL was evident, showing that the previously mentioned mediastinal adenocarcinoma may be derived from the epithelial elements of LECL. This paper discusses the histogenesis of LECL.

Entities:  

Mesh:

Year:  1989        PMID: 2556020     DOI: 10.1093/ajcp/92.6.808

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

1.  Lymphoepithelial cyst of the mediastinum.

Authors:  Refik Ulku; Fahri Yilmaz; Sevval Eren; Serdar Onat
Journal:  Tex Heart Inst J       Date:  2005

2.  Lymph node cancer of the mediastinum with a putative necrotic primary lesion in the lung: a case report.

Authors:  Daichi Shikata; Takahiro Nakagomi; Rumi Higuchi; Yujiro Yokoyama; Toshio Oyama; Taichiro Goto
Journal:  World J Surg Oncol       Date:  2018-04-02       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.